Spots Global Cancer Trial Database for Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
Official Title: CT-2103/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of PS = 2 Patients With Chemotherapy Naive Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase III Study
Study ID: NCT00054210
Conditions
Study Description
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of chemotherapy is more effective in treating stage IIIB, stage IV, or recurrent non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of polyglutamate paclitaxel plus carboplatin to that of paclitaxel plus carboplatin in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer.
Detailed Description: OBJECTIVES: * Compare the efficacy of polyglutamate paclitaxel (CT-2103) and carboplatin vs paclitaxel and carboplatin, in terms of duration of overall survival, in patients with stage IIIB or IV or recurrent non-small cell lung cancer who have a performance status of 2. * Compare the disease control (percentage of patients with no disease progression for at least 12 weeks) and time to progression in patients treated with these regimens. * Compare the response rate in patients with measurable disease treated with these regimens. * Compare the improvement in lung cancer symptoms in patients treated with these regimens. OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to gender, disease stage (IV vs other), geographic location (US vs Western Europe and Canada vs the rest of the world), and prior brain metastases (yes vs no). Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive polyglutamate paclitaxel (CT-2103) IV over 10 minutes and carboplatin IV over 30 minutes on day 1. * Arm II: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats in both arms every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed at 3 weeks and then every 8 weeks thereafter. PROJECTED ACCRUAL: A total of 370 patients (185 per treatment arm) will be accrued for this study within 13 months.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hematology and Oncology Associates of Alabama, Birmingham, Alabama, United States
Clinical Research Consultants, Inc, Hoover, Alabama, United States
Arizona Clinical Research Center, Tucson, Arizona, United States
Synergy Hematology/Oncology Medical Associates, Encino, California, United States
Holy Cross Providence Cancer Center, Mission Hills, California, United States
Clinical Trials and Research Associates, Incorporated, Montebello, California, United States
California Hematology/Oncology Medical Group, Torrance, California, United States
Hematology Oncology, P.C., Stamford, Connecticut, United States
New Hope Cancer Centers, Hudson, Florida, United States
Omni Healthcare, PA, Melbourne, Florida, United States
MetCare Oncology, Ormond Beach, Florida, United States
Hematology Oncology Associates of theTreasure Coast - Port St. Lucie, Port Saint Lucie, Florida, United States
Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States
Georgia Cancer Specialists - Tucker, Tucker, Georgia, United States
Silver Cross Hospital, Joliet, Illinois, United States
Gross Point Medical Center, Skokie, Illinois, United States
Kentucky Cancer Clinic, Pikeville, Kentucky, United States
, Grand Rapids, Michigan, United States
Hattiesburg Clinic, P.A., Hattiesburg, Mississippi, United States
Columbia Comprehensive Cancer Care Clinic, Columbia, Missouri, United States
Bond Clinic, Rolla, Missouri, United States
Las Vegas Cancer Center, Las Vegas, Nevada, United States
Summit Medical Group, P.A., Summit, New Jersey, United States
Gabrail Cancer Center - Canton Office, Canton, Ohio, United States
Oklahoma Oncology, Inc. - St. John Campus, Tulsa, Oklahoma, United States
Charleston Cancer Center, Charleston, South Carolina, United States
Santee Hematology Oncology, Sumter, South Carolina, United States
Clarksville Regional Hematology/Oncology Group, Clarksville, Tennessee, United States
Family Cancer Center, Collierville, Tennessee, United States
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Cancer Therapy and Research Center, San Antonio, Texas, United States
Virginia Oncology Care P.C., Richlands, Virginia, United States
Highline Medical Oncology, Burien, Washington, United States
Rainier Oncology, Puyallup, Washington, United States
Cross Cancer Institute, Edmonton, Alberta, Canada
Contact Details
Name: Melinda Bomar
Affiliation: PPD, Incorporated
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
